Theriva Biologics, Inc. (TOVX)
NYSEAMERICAN: TOVX · Real-Time Price · USD
0.3450
+0.0030 (0.88%)
At close: Oct 24, 2025, 4:00 PM EDT
0.3084
-0.0366 (-10.61%)
After-hours: Oct 24, 2025, 8:00 PM EDT
Theriva Biologics Employees
Theriva Biologics had 22 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
22
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,343,364
Market Cap
3.31M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 22 | 0 | - |
| Dec 31, 2023 | 22 | 1 | 4.76% |
| Dec 31, 2022 | 21 | 5 | 31.25% |
| Dec 31, 2021 | 16 | 6 | 60.00% |
| Dec 31, 2020 | 10 | -1 | -9.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TOVX News
- 2 days ago - Theriva Biologics Provides Response to Unusual Market Action - GlobeNewsWire
- 10 days ago - Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds - GlobeNewsWire
- 20 days ago - Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) - GlobeNewsWire
- 2 months ago - Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results - GlobeNewsWire
- 5 months ago - Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results - GlobeNewsWire
- 6 months ago - Theriva Biologics Announces Closing of $7.5 Million Public Offering - GlobeNewsWire
- 6 months ago - Theriva Biologics Announces Pricing of $7.5 Million Public Offering - GlobeNewsWire
- 7 months ago - Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - GlobeNewsWire